



Preferred Reporting Of Case Series in Surgery (PROCESS) 2023 guidelines

Ginimol Mathew, MBBS, BSc, PGCert^{a,*}, Catrin Sohrabi, BSc, PhD, MBBS^a, Thomas Franchi, MBCh, MSc, FHEA, MAcadMED^e, Maria Nicola, MD, MRCS^c, Ahmed Kerwan, MBBS, MSc^d, Riaz Agha, BSc, MBBS, MSc, D.Phl, MRCS Eng^b; PROCESS Group

Introduction: The Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines were developed in 2016 in order to improve the reporting quality of surgical case series. Since its inception, it has been updated twice, in 2018 and 2020, and has been cited over 1000 times. PROCESS guidelines have enjoyed great acceptance within the surgical research community. Our aim is to update the PROCESS guidelines in order to maintain its applicability in the field of surgical research.

Methods: A PROCESS 2023 steering group was created. By working in collaboration, members of this group came up with proposals to update the PROCESS 2020 guidelines. These proposals were presented to an expert panel of researchers, who in turn scrutinised these proposals and decided whether they should become part of PROCESS 2023 guidelines or not, through a Delphi consensus exercise.

Results: A total of 38 people participated in the development of PROCESS 2023 guidelines. The majority of items received a score between 7 and 9 from greater than 70% of the participants, indicating consensus with the proposed changes to those items. However, two items (3c and 6a) received a score between 7 and 9 from less than 70% of the participants, indicating a lack of consensus with the proposed changes to those items. Those items will remain unchanged.

Discussion: The updated PROCESS 2023 guidelines are presented with an aim to continue improving the reporting quality of case series in surgery.

Keywords: PROCESS, reporting guidelines, surgical case series

Introduction

A case series is an observational study, which involves following a particular group of patients with a similar disease or exposure/intervention, over a specific period of time, in order to study their characteristics and outcomes, in the absence of a control group^[1]. Although case series come lower down in the hierarchy of evidence, they are among the most commonly published studies in the surgical literature^[2]. Additionally, despite the utility of case series being contested, they can add to the scientific literature in several ways such

^eRoyal Free London NHS Foundation Trust, ^bHarley Clinic Group, 10 Harley Street, ^cImperial College Healthcare NHS Trust, ^dGuy's and St Thomas' NHS Foundation Trust, London and ^eOxford University Hospitals, NHS Foundation Trust, Oxford, UK Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

*Corresponding author. Address: Royal Free London NHS Foundation Trust, United Kingdom. Tel.:/fax: +44 020 7794 0500. E-mail: ginimol.mathew.13@ucl.ac.uk (G. Mathew).

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

International Journal of Surgery (2023) 109:3760-3769

Received 11 September 2023; Accepted 10 November 2023

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.lww.com/international-journal-of-surgery.

Published online 20 November 2023

http://dx.doi.org/10.1097/JS9.00000000000000940

HIGHLIGHTS

- We present an updated version of Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines; they were first published in 2016 in order to improve the reporting quality of surgical case series.
- Updated PROCESS 2023 guidelines were produced using a
 Delphi consensus exercise. A total of 38 people participated in the development of PROCESS 2023 guidelines
 and there was a high level of agreement among the Delphi
 group members with the proposed amendments to the
 PROCESS 2020 guidelines.
- We present PROCESS 2023 guidelines with an aim to continue improving the reporting quality of surgical case series.

as describing rare diseases, unusual presentations of a common disease, novel interventions, and unexpected results of an intervention^[3].

A systematic review published in 2016 showed that the methodological and reporting quality of case series in surgery were below par and required improvement^[4]. In order to better the reporting quality among surgical case series and hence increase their trustworthiness and usefulness, the Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines were developed in 2016^[5]. Subsequently, the PROCESS guidelines were updated in 2018 and 2020^[6,7].

PROCESS 2020 guidelines and the proposed version of PROCESS 2023 guidelines.

Topic	Item	PROCESS 2020	Proposed PROCESS 2023
Title	1	The phrase 'case series' and the area of focus should appear in the title (e.g. patient population, diagnosis, intervention or outcome).	The phrase 'case series' is included The focus of the research study is mentioned (e.g. patient population, setting, diagnosis,
Keywords	2	Include three to six keywords that identify what is covered in the case series (e.g. patient population, diagnosis, intervention or outcome). Include 'case series' as one of the keywords.	intervention, outcome etc.) Include three to six keywords that identify what is covered in the case series (e.g. patient population, setting, diagnosis, intervention, outcome etc.) Include 'case series' as one of the keywords
Abstract	3a	Introduction and Importance Describe what is unique or educational. What is the overarching theme of the case series?	 Include the surgical subspeciality the case series pertains to as a keyword Introduction – briefly describe: Background Scientific rationale for this study Overarching theme of the case series Aims and objectives
	3b	Methods • Describe what was done, how and when was it done and by whom.	Methods – briefly describe: Sample size Timeframe of research Characteristics of study design (e.g. prospective/retrospective, single-/multicentre, informal/formal, consecutive/nonconsecutive, exposure-/outcome-based sampling, clinical/population-based etc.)
	3c	Outcomes Describe the outcomes of the intervention and management strategy.	Results – briefly describe: Outcomes of the intervention/management strategy
	3d	Conclusion Describe the take-home message(s), including what has been learnt? How will this impact future clinical practice?	Conclusion – briefly describe: • Key findings and take-home messages • Impact on future clinical practice • Direction of future research
	3e		Present a structured abstract Informal case series – introduction, case presentations (brief description of each case) and discussion/conclusion Formal case series – introduction, methods, results and discussion/conclusion
Highlights Introduction	4 5	Describe the background of the case series and specify the overarching theme (e.g. common disease, intervention, or outcome). The introduction should explain what is unique or educational about the case series. Relevant scientific literature should be referenced.	Convey the key findings of the research study in 3–5 bullet points Introduction – comprehensively describe: Relevant background and scientific rationale for case series with reference to key scientific literature Overarching theme (e.g. common patient population, setting, diagnosis, intervention, outcome etc.)
Methods	6a	Registration State the research registry number in accordance with the Declaration of Helsinki - "Every research study involving human subjects must be registered in a publicly accessible database". This can be obtained from, for example, ResearchRegistry. com, ClinicalTrials.gov, or ISRCTN. If a protocol already exists, state the corresponding registration number and access directions (e.g. website or journal, and include a hyperlink that is publicly	 Aims and objectives Registration In accordance with the Declaration of Helsinki*, state the research registration number and where it was registered, with a hyperlink to the registry entry (this can be obtained from ResearchRegistry.com, ClinicalTrials.gov, ISRCTN etc.) All retrospective studies should be registered before submission; it should be stated that the research was retrospectively registered "Every research study involving human subjects must be registered in a publicly
	6b	accessible). It must be written in the English language.	accessible database before recruitment of the first subject" Protocol If a protocol exists, state the corresponding registration number and access directions (e.g. website or journal, and include a hyperlink that is publicly accessible). It must be written in the English language.
	6c		Ethical approval State whether ethical approval was needed or not, with reason(s) If appropriate, state name of body giving ethical approval and approval number
	6d	Study Design State that the study is a case series. State whether the case series is: (1) prospective/retrospective, (2) single/multicentre, and if (3) cases are consecutive/nonconsecutive.	Study design State that the study is a case series Describe key characteristics of study design (e.g. prospective/retrospective, single-/multicentre, informal/formal, consecutive/nonconsecutive, exposure-/outcome-based sampling, clinical/population-based etc.)
	6e	Settings and Time-Frames Describe the setting(s) in which the patient was managed (e.g. research institution, teaching/district general hospital, community, or private practice). Document any relevant dates (e.g. recruitment, intervention, follow-up, and data collection time-frames).	Setting and timeframe – comprehensively describe: Geographical location Nature of setting(s) where the patient was managed (e.g. primary/secondary/tertiary care setting, district general hospital/teaching hospital, public/private, low-resource setting etc.) Relevant dates (e.g. recruitment, intervention, follow-up, data collection etc.)
	6f	Participants Describe the relevant characteristics (e.g. demographics, comorbidities, tumour staging, smoking status) and if relevant, exposure(s) of the participants. Describe the method of participant recruitment, if relevant. State any subsequent inclusion or exclusion criteria, and how the participants were selected. Methods used to ensure the de-identification of patient information.	Participants – comprehensively describe: Relevant participants characteristics (e.g. demographics, comorbidities, ASA score, severity of surgery, urgency of surgery, smoking status, turnour staging etc.) and if relevant, exposure(s) of the participants (e.g. COVID-19) Subsequent inclusion and exclusion criteria with clear definitions Approach to selecting patients (e.g. consecutive/nonconsecutive, exposure-/outcome-based, formal/informal etc.) Methods used to ensure de-identification of patient information
	6g		Recruitment – comprehensively describe: Sources of recruitment (e.g. physician referral, electronic health record etc.) Any monetary incentivisation of patients for recruitment and retention should be declared; clarify the nature of any incentives provided
	6h	Preintervention Patient Optimisation • Lifestylie (e.g. weight loss). • Medication review (e.g. anticoagulation, oral hypoglycemics/insulin). • Presurgical stabilisation/preparation (e.g. treating hypothermia/hypovolemia/hypotension, ICU care for sepsis, nil by mouth, or enema). • Other (e.g. psychological support).	Preintervention patient optimisation: Lifestyle (e.g. weight loss, nutritional support, exercise, smoking cessation etc.) Medication review (e.g. anticoagulation, oral hypoglycemics, insulin, oral contraceptive pill etc.) Presurgical stabilisation/preparation (e.g. treating hypothermia/-volemia/-tension, ICU care, nil by mouth, bowel preparation etc.) Other (e.g. psychological support, preoperative education/counselling etc.)
	6i	Interventions Describe the type(s) of intervention(s) used (e.g. pharmacological, surgical, physiotherapy, psychological, preventative).	Time (e.g. psychological support, presperance education/counseling etc.) Interventions – comprehensively describe: Type of intervention (e.g. pharmacological, surgical, physiotherapy, psychological etc.) Aim of intervention (preventative/therapeutic)

(Continued)

the interface interface projects years; If the restortion Dealth For deriver to Dealth For deriver to the projects of the project of the projects of the pr	Topic	Item	PROCESS 2020	Proposed PROCESS 2023
Figure 1 intervention Deaths - Extraction for articolous facility of the patient of christs, you if was profound and this is a few profound on the first of the control of the control of the control of the control of the contr				Concurrent treatments (e.g. antibiotics, analgesia, antiemetics, venous
Placebole multi-unitwo before the resource reflected, look as populational and treat interest continued. For example, route and admition. For example, route and example and present and position of the learning own any interest country and admitished must do part and present year. For example, route and example, route and example and admitished route and position of the learning own and admitished and admitished route and admitish		C:		
For demandingfull thereages, include information or the formation, design, strongers, or of amounting of an incompletion services, used of the relevant expansers, utilized, debter, and support of more than a support or more than		bJ		
interest, note and controls • For entirely, include debtile such as immediated, performance controls • The deptive of control of an august allowed based or immediated by a first in interest of the present control. • Posterial debties should be controlled based or immediated by a first in interest of the present control. • Posterial debties should be controlled beautiful interested by a first interest of the present control of the present control of the present features. • Who congreticals include presents on present or present o				
For surging, notice details and his anaetheless guided postinis, repearation soci, use of other pitters of others, but a surgict allering and surgices (see an automate size). In the degree of riverty for a surgice allering accordance included lag. That is a surgice allering accordance in control and lag. That is a control of control and the surgices and the control of control and the surgices and the control of control and the control and the surgices and the control of control and the control and the surgices and the control of control and the control and the control of control and the control and the control of control and the control and the control and the control of control of control and the control of control of control and the control of control and the control of control of control and the control of control of control and the control of control of control of control and the control of co				
The degree of mostly in the manufacture and model specifically mentioned. 6x Operand betails 6x Operand			• • • • •	 For pharmacological therapies, include details such as formulation, dosage, strength,
The danger of rowshy first a supplied introduced was should be mentioned leg., from his harmor of river in the control. Notical divious should have manufacture and model appoiliculty mentioned. Be Where applicable, models occurring evaporation and position on the home of surgicular scools by taking in Photos Stopper and appoiliculty mentioned. Be Where applicable, models occurring evaporation on the home of surgicular scools by taking in Photos Stopper and societies conduction on the home of surgicular scools by taking in Photos Stopper and societies conducted produced in the control training, and to manufacture conduction of the surgicular scools by the surgi				
A feed of devices should have manufactures and model appelloading metabones. Where applicable include operative epidentice and policies on the learning curres way. Where applicable include operative epidentice and policies on the learning curres way. Where a policialized in a consistent on any face framework in a special displaced spootably intering in Pacific Signey and seven series cases completed previously work for the apportunity of the consistent on any face of series of supplied appointment of the consistent on any face of series of supplied and policy and the consistent on any face of series of series of supplied and series of series of supplied and series of series				
Pleasure Departs Operator Details Operator Det				• Degree of novelty of surgical technique/device (e.g. 'first in human' or 'first in this
Contract footballs Vertice registrates, includit operator sepretures are position on the learning curves, any research stancing, and speciations pile. Journal trainery, and speciations pile. Journal trainery, and speciations pile. Journal trainery, and speciations posterine causes are judiportation to submit to supervisions. State any specific department consideration proteoner causes ago, pulsepartment in a validation. State any specific department control control proteoner causes ago, pulsepartment or submit to the service of extending and the service control proteoner. Very specific in part or submit to submit to submit to the service of extending and the service control proteoner. Protection of the submit to			 Medical devices should have manufacturer and model specifically mentioned. 	
Wines applicable, include operation experience and profition on the learning came, any reconstitutings, applicability starting in Plates's Surpey and attent minimiz cases compiled proxivation (b). O Suity Control Will measures were taken to induce outsidence, by the control of		6k	Operator Details	
Billion of the control processory and severe similar cases completed processory and reference specification of the control processory and the control intervention of the control processory and the control intervention of the control processory and the control intervention of the control processory and the control processory and the control processor and				Relevant training, specialisation and operator's experience (e.g. average number of the
Learning care for schrighage				relevant procedures performed annually, independent, needs direct/indirect
A Caulty Control What in recursive were belien to reduce inter- or intra-constant/repersion variation, to results quality, and to result quality, and to results quality, and to results quality, and to result quality, and to result quality, and to result quality, and to result quality and the production of the products and quality and the production of the produce of passing the production of the product of the product of the product quality and the productions and the passing of the production of the productio				•
Visitar incourage were table to reduce free or intra operator/logoration visition, to estable quality of the ministing constraints of the ministing of the ministing of the protection of the protection of the ministing of the			under direct supervision j.	
estate quality, and the maintain consistancy between cases (e.g., independent electrones), injurish one courts, standard argund institutions, and provided departise between cases. Follow-up When is quarter and objective constitution, primary case, according and the constitution of th		61		
State any specific departies between cases Follow-lip F				Measures taken to reduce inter- or intra-operator/operation variation, ensure quality and maintain consistency between access (a.g., independent absolutes).
Position in the participant is between cases. Follow-Up required departities between cases. Follow-Up and after discharge, frequency, maximum follow-up length at the time of automicisms. • Where is put horizon consultation, principant care discharge, frequency cared, who is a put of consultation, primary case, account of consultation of consultation, primary case, account of consultation, primary case, account of consultation of consultation, primary case, account of consultation of consultation, primary case, account of patients in consultation, primary case, account of consultation of consultation, primary case, account of consultation of consultation, primary case, and consultation of consultation of consultation, primary case, and consultation of consultation of consultation of consultation of consultation of co				
* When is, how long ther dicharge, frequency, maximum follow up length at the time of statismission!, * Where is, p. Inferior consultation, primary care, secondary core, how pays called physicisters, and extend principles of entroperation reasons reconsultation, primary particularly a prediction of entroperation reasons reconsultation, primary proprieting and proposition of entroperation reasons reconsultation, primary proprieting and the patient characteristics (e.g., demographics, correctedibles, emoking status, and if applicables, throat staging (e.g., TMM0).				
the of submission). • Whore or, but how a vide consultation, primary care, secondary care). • Whore or, but how a vide consultation, primary care, secondary care). • Any specific but your barm survitains compliants, blood tests, inaging). • Any specific but your barm survitains configural primary notes for Sci cancelly. • Any specific but your barm survitains configural primary care of discussions and submissional primary care of discussions are provided and survivance of a photocontraction and survivance of the primary care of survivance of the primary care of submissional primary care of survivance of the primary care of survivance of the primary care of survivance of the primary care of th		6m	•	
Persults Particular of the properties of the particular department (a) Persults Polymer of the particular department (a) Persults Persults Persults Persults Polymer of the particular department (a) Persults Persult				
Follow up to far participating controllation, clinical examination, blood tests, imaging). Any specific top plems survivalence requirements (e.g., integring surveillance of endouscoular amonymen repair or clinical examinations, thorough surveillance of physiomiserapy, specificograft hereby?). State if any participants were lost to fotov-up and vilvy. State if any participants were lost to fotov-up and vilvy. Participants Part			,	
eriox-secular anusyme repair or clinical examultinesound of regional lymph nodes for fish cancers) - Any specific postsperative instructions (e.g., postsperative medications, targeted physichinary, psychological through) State if any participants were lost to follow-up and why. - Participants - Peaculosants - Peace state the number of patients invoked, the patient characteristics (e.g., demonstration) of mobile for sistic cancer etc.) - State of three were any changes in the planned intervention(§ e.g., what was changed and why Peace include a sublable schematic diagram if appropriate Peace and and very any charges in the planned intervention(§ e.g., what was changed and why Peace include a sublable schematic diagram if appropriate Peace include a sublable schematic diagram in a propriate Peace include a sublable schematic diagram in a propriate Peace include a sublable schematic diagram in a propriate Peace include a sublable schematic diagram in a propriate Peace include a sublable schematic diagram in a propriate Peace include a sublable schematic diagram in a propriate Peace include a sublable schematic diagram in a propriate Peace				• Follow-up time-frames (e.g. first follow-up postdischarge, follow-up duration at the time
for skin cancer). Apy specific patchgrantwe instructions (e.g., postoparative medications, targeted physiotherapy, psychological therapy). State if any participants were lost to follow-up and why. Participants Participants				, , ,
Participants Results 7a Participants Participants Phase state the number of patients invoked, the patient characteristics (e.g., demographics, comorbidities, smoking status, and if applicable, tumour staging (e.g. TNM). Phase state the number of patients invoked, the patient characteristics (e.g., demographics, comorbidities, smoking status, and if applicable, tumour staging (e.g. TNM). Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate. Outcomes and Follow-lip Phase include a suitable schematic diagram if appropriate, include platein response dimension in the propriate including quality effect scales in the precision appropriate include platein response dimension in the propriate include platein response dimension in the propriate including appropriate, include platein response diminish and platein appropriate, include platein response diminish and platein law and follow-up and interventional development and intervention and inte				
Results 7a Participants vere last to follow-up and why. Participants Peace state the number of patients involved, the patient characteristics (e.g. demographics, comorbidities, smoking status, and if applicable, turnour staging (e.g., TNM). Description from the Initial Management Plan State If there were any charges in the planned intervention(s) (e.g., what was changed and why). Passes include a suitable schematic diagram if appropriate. Description and replan vulley of the participants of the pa			•	 Follow-up method (e.g. history, clinical examination, blood tests, imaging etc.)
Passults 7a Participants Please state the number of patients involved, the patient characteristics (e.g., demographics, comorbidities, smoking status, and if applicable, humour staging (e.g. TMM). 7b Deviation from the initial Management Plan State if there were any changes in the planned intervention(s) (e.g., what was changed and why). 1 Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up 1 Describe and explain the percentage of patients foot to follow-up. Intervention Adherence and compliance Phenotherapy and pharmacological agents). 2 Describe and explain the percentage of patients described in dard before provided (e.g., avoiding how) within the operated informance were measured. 7c Complications and Adverse Events Presultionary measures staten to prevent complications (e.g., antibiotic or venous thromboembolism prophylassis). 3 Percentage in patients to follow-up on the terrenation where the provided (e.g., avoiding how) within got advantional auragey, or tolerance of chemotherapy and pharmacological agents). 4 Complications and Adverse Events Presultionary measures staten to prevent complications (e.g., antibiotic or venous thromboembolism prophylassis). 5 Pagin the outside on the legisland events should be described in detail and ideally categorized in accordance with the Clavers—Dindo Classification (e.g., blood loss, legisland) in the expected timeframe (if not, why not). 4 Where applicable, the 30-48 postpoartable and onlong—mm modifyl/mortally may need to be specified. 5 State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.				
Pesults 7a Participants Perticipants Pertic			 State if any participants were lost to follow-up and why. 	
Pesuls 7a Participants - Please state the number of patients involved, the patient characteristics (e.g., after participants - Please state the number of patients involved, the patient characteristics (e.g., after participants - comprehensive) describe: - Namber of patients involved - Please state the number of patients involved and very (e.g., TNM)). 7b Deviation from the initial Management Plan - State if there were any changes in the planned intervention(s) (e.g., what was changed and viry). 7c Duttomes and Follow-Up - Expected versus statinate clinical outcome as assessed by the clinician. Peterenoe illerature used to inform expected outcomes. • When appropriate, include a suitable schematic diagram of period patient reported measures (e.g., questionnaires including quality-cl-file scales). • Describe and explain the percentage of patients lost to follow-up. Intervention Artherone and Compliance - Where relevant, detail how well the patient adversed to and tolerated the advice provided (e.g., avoiding heavy filting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents; e.g., questionnaires including and ideally and intervention and device provided (e.g., avoiding heavy filting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents; e.g., artibiotic or venous thromoheroidism prophylaxis. • Explain how adherence and tolerance were measured. Complications and Adverse very unablicated events should be described in detail and indexing explanation of the patient in the complex of the patient intervention and discharge, and whether this was within the expected to the relevant national agency or phermacolitical company. • Specify the duration of time between complications or adverse outcomes If relevant, was the complications or adverse outcomes Discussion 8a Summarise the key results.				
Please state the number of patients involved, the patient characteristics (e.g., demographics, comorbidities, smoking status, and if applicable, tumour staging (e.g. TNM). 7b Deviation from the latied Management Plan State if there were any changes in the planned intervention(s) (e.g. what was changed and why). Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up Intervention Adherence and Compliance Outcomes and follow-up - comprehensively describe: Operation from expected outcomes. Where replaced, the 30 year, any outcome and follow-up - intervention Adherence and Compliance Outcomes and follow-up - comprehensively describe: Opinion how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for addominal surgery, or tolerance of chemotherapy and pharmacological agents: C. Opinications and Adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Caiver-Tomoto. Callsaffaction (e.g., ambition or version surgery, impact on length of stay). It relevant, uses the complications propriets in the Caiver-Tomoto. Callsaffaction (e.g., blood loss, length of operative time, wound complications; re-exploration or revision surgery etc.) It relevant, use the complication reported to the relevant national agency or pharmacolicical agents and the callsaffaction (e.g., blood loss, length of stay). It relevant, was the complications or adverse outcomes Discussion Ba Summarise the key results.				
demographics, comorbidities, smoking status, and if applicable, tumour staging (e.g. TNM). Deviation from the Initial Management Plan State If there were any changes in the planned intervention(s) (e.g. what was changed and why). Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up Depocted versus attained clinical outcome as assessed by the clinican. Perference literature used to inform expected outcomes. When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). Describe and explain the percentage of patients lost to follow-up. Percentage of patients lost to follow-up. Intervention Adherence and Compliance Where relevant, detail how well the patient athered to and tolerated the advice provided (e.g., avaiding heavy little) (or advisional surgery, or tolerance of chemotherary and pharmacological agents). Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromothosimos prophylaxs); All complications and adverse events where the complexion of the intervention and dischards, and whether this was within the expected intervention (e.g. avaiding heavy) intervention in clinical practice complications and adverse events (e.g. blood loss, length of stay). If relevant, was the complication reported to the relevant national agency or pharmacological agents with the expected intervention and discharge, and whether this was within the expected intervention and discharge, and whether this was within the expected intervention and discharge, and whether this was within the expected intervention and discharge, and whether this was within the expected intervention and intervention and expected outcomes (e.g. avaiding heavy) or a specification (e.g. avaiding heavy) in the expected and complications or adverse events were reportant and appropriate whether complications or adverse events were reportant a	Results	7a	·	
(e.g. TNM)). Deviation from the initial Management Plan State if there were any charges in the planned intervention(s) (e.g., what was changed and why). Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up Expected versus attained clinical outcome as assessed by the clinician. Reference literature used to inform expected outcomes. When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). Describe and explain the patient adhered to and tolerated the advice provided (e.g., avoiding heay) filting for aboldminal surgery, or tolerance of chemotherapy and pharmacological agents). Explain how adherence and Otomplication for provided (e.g., avoiding heay) filting for aboldminal surgery, or tolerance of chemotherapy and pharmacological agents). Procrationary measures telant to prevent complications (e.g., antibiotic or venous thromoboembolism prophylasis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavier-Dindo Classification (e.g., blood loss, length of operative time, wound complications, e-ap-point no revision surgery, impact on length of stay). Price levant, was the complication reported to the relevant national agency or pharmacological agents etc.) Price levant, was the complication or prothydavis). In relevant, was the complication or prothydavis, and whether this was whith the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.				
Poekation from the Initial Management Plan				surgery, urgency of surgery, smoking status, tumour staging etc.) and if relevant,
Deviation from the Initial Management Plan State if there were any changes in the planned intervention(s) (e.g. what was changed and why). Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up Depected versus attained clinical outcome as assessed by the clinician. Reference literature used to inform expected outcomes. When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). Describe and explain the percentage of patients lost to follow-up. Intervention Adherence and Compliance Where relevant, cleah how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents). Deptian how adherence and tolerance were measured. Complications and Adherese Events Presautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Unido Classification (e.g. blood loss, length of perative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmacoulical company; Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results.				exposure(s) of the participants
State if there were any changes in the planned intervention(s) (e.g. what was changed and why). Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up Expected versus attained clinical outcome as assessed by the clinician. Reference literature used to inform expected outcomes. When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). Discorbe and explain the percentage of patients lost to follow-up. Intervention Adherence and Compliance Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. auditing heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents). Precautionary measures taken to prevent complications (e.g. antibiditic or venous thromboembolism prophylaxis). All complications and Adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clariera-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmacoulical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.		7h	Davistics from the Initial Management Disp	
and why). Please include a suitable schematic diagram if appropriate. Outcomes and Follow-Up Expected versus attained clinical outcome as assessed by the clinician. Reference literature used to inform expected outcomes. When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life caseles). Describe and explain the percentage of patients lost to follow-up. Intervention Atherence and Compliance Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for addominal surgery, or tolerance of chemotherary and pharmacological agents). Explain how adherence and tolerance were measured. Percautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and Adverse Events Precautionary and adverse events (e.g. alto load and deall and deall) categorised in accordance with the Clavien-Dindo Classification (e.g. and whether this was within the expected timeframe (if not, why not). If relevant, was the complications reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidily/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.		70		
Outcomes and Follow-Up				
Expected versus attained clinical outcome as assessed by the clinician. Reference literature used to inform expected outcomes. When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). Describe and explain the percentage of patients lost to follow-up. Intervention Adherence and Compliance Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents). Explain how anderence and volerance were measured. Complications and Adverse Events Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the undeation of time between completion of the intervention and discharge, and whether this was within the expected timefarme (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Biscussion 8a Summarise the key results.		_		•
Iterature used to inform expected outcomes. • When appropriate, include patient-reported measures (e.g. questionnaires including quality-of-life scales). • Describe and explain the percentage of patients lost to follow-up. Intervention Atherence and Compliance • Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g., avoiding heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacollogical agents). • Explain how adherence and tolerance were measured. Complications and Adverse Events • Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). • All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). • If relevant, was the complication reported to the relevant national agency or pharmaceutical company. • Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). • Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. • State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.		/C	·	
quality-of-life scales). • Describe and explain the percentage of patients lost to follow-up. Intervention Adherence and Compliance • Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents etc.) • Explain how adherence and tolerance were measured. Complications and Adverse Events • Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). • All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). • If relevant, was the complication reported to the relevant national agency or pharmacoutical company. • Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). • Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. • State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.				literature used to inform expected outcomes (e.g. core outcome set)
Discussion Discu			 When appropriate, include patient-reported measures (e.g. questionnaires including 	 If appropriate, include patient-reported outcomes (e.g. quality-of-life)
Intervention Adherence and Compliance Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting or abdominal surgery, or tolerance of chemotherapy and pharmacological agents). Fe Spilain how adherence and tolerability of intervention a cinstructions (e.g. avoiding heavy lifting/strenuous activity, tolerance of chemotherapy and pharmacological agents). Fe Complications and Adverse Events Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien—Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results.				 Percentage of patients lost to follow-up with rationale
Where relevant, detail how well the patient adhered to and tolerated the advice provided (e.g. avoiding heavy lifting for abdominal surgery, or tolerance of chemotherapy and pharmacological agents). Explain how adherence and tolerance were measured. Complications and Adverse Events Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion Ba Summarise the key results. **Assessment of patient's adherence and tolerability of intervention and instructions (e.g. avoiding heavy lifting/strenuous activity, tolerance pharmacological agents etc.) *Impact on long-term applicability of intervention in clinical practice Complications and adverse events — Precautions and adverse events to complications end adverse events thromboembolism prophylaxis) Oromplications and adverse events (e.g. blood loss, wound infection thromboembolism prophylaxis) *Complications and adverse events (e.g. blood transfusion, vound care, revision surgery etc.) *I flappropriate, whether complications or adverse events were discurated to be specified. State if there were no complications or adverse events were reportant adverse events event		7d		Intervention adherence and compliance — comprehensively describe:
chemotherapy and pharmacological agents). Explain how adherence and tolerance were measured. Complications and Adverse Events Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results. Explain how adherence and tolerance were measured. Complications and adverse events (e.g. blood loss, antibiotic or venous thromboembolism prophylaxis) Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis) Precautionary measures taken to prevent complications or revision surgery etc.) Complications and adverse events (e.g. blood loss, antibiotic or venous thromboembolism prophylaxis) Precautionary measures taken to prevent complications or adverse events (e.g. blood loss, wound infection thromboesis, pulmonary embolism etc.), categorised in accordance Dindo classification Timing of adverse events (e.g. blood transfusion, wound care, revision surgery etc.) If appropriate, whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term s				Assessment of patient's adherence and tolerability of intervention and postoperative
Explain how adherence and tolerance were measured. Complications and Adverse Events Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien—Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results. Explain how adherence and tolerance were measured. Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, lost intrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism prophylaxis) Complications and adverse events (e.g. blood transfusion, outperse events (e.g. blood transfusion, outperse events (e.g. blood tran				instructions (e.g. avoiding heavy lifting/strenuous activity, tolerance of chemotherapy/
Complications and Adverse Events Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis). All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien—Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Complications and adverse events — comprehensively describe: Precautionary measures taken to prevent complications (e.g. antibiotic or venous thromboembolism prophylaxis) Complications and adverse events (e.g. blood loss, wound infection thromboesis, pulmonary embolism etc.), categorised in accordance Dindo classification Timing of adverse events (e.g. blood transfusion, wound care, revision surgery etc.) If appropriate, whether complications or adverse events were discumorbidity and mortality meetings) If appropriate, whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term expected t				
thromboembolism prophylaxis). • All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavien—Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). • If relevant, was the complication reported to the relevant national agency or pharmaceutical company. • Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). • Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. • State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. thromboembolism prophylaxis) • Complications and adverse events (e.g. blood loss, wound infectior thrombosis, pulmonary embolism etc.), categorised in accordance Dindo classification • Timing of adverse events (e.g. blood transfusion, wound care, revision surgery etc.) • If appropriate, whether complications or adverse events were eliscu morbidity and mortality meetings) • If appropriate, whether complications or adverse events were repor national agency or pharmaceutical company • Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) • Where applicable, specify the 30-day postoperative and long-term • State if there were no complications or adverse events Key results—comprehensively describe: • Key results—comprehensively describe: • Key results—two traves are events (e.g. blood transfusion, wound care, revision surgery etc.) • If appropriate, whether complications or adverse events were repor national agency or pharmaceutical company • Specify time to discharge following completion of intervention and tweetings and the propriate of the revision surgery etc.) • Where applicable, a venture of the propriate of the revision surgery etc.) • Where applicable		7e		
All complications and adverse or unanticipated events should be described in detail and ideally categorised in accordance with the Clavlen-Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results. Summarise the key results. Summarise the key results. Complications and adverse events (e.g. blood loss, wound infection thrombosis, pulmonary embolism etc.), categorised in accordance Dindo classification Timing of adverse events (e.g. blood transfusion, outled classification) Timing of adverse events (e.g. blood transfusion, outled classification) Timing of adverse events (e.g. blood transfusion, wound care, revision surgery etc.) If appropriate, whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term exists with relevant raw data Include table showing key results				 Precautionary measures taken to prevent complications (e.g. antibiotic/venous
and ideally categorised in accordance with the Clavien—Dindo Classification (e.g. blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Thrombosis, pulmonary embolism etc.), categorised in accordance Dindo classification Timing of adverse events (e.g. blood transfusion, wound care, revision surgery etc.) It may reportate, whether complications or adverse events were discumentally meetings) If appropriate, whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timerfame or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term State if there were no complications or adverse events Key results—comprehensively described. Reversells with relevant raw data Include table showing key results				
blood loss, length of operative time, wound complications, re-exploration or revision surgery, impact on length of stay). If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion Ba Summarise the key results. Dindo classification Timing of adverse events Mitigation for adverse events (e.g. blood transfusion, wound care, revision surgery etc.) If appropriate, whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term or papilications or adverse events. Experimentally applicable, specify the 30-day postoperative and long-term or papilications or adverse events. Experimentally applicable, specify the 30-day postoperative and long-term or papilications or adverse events. Experimentally applicable, specify the 30-day postoperative and long-term or papilications or adverse events. Experimentally applicable, specify time 30-day postoperative and long-term or papilicable, specify the 30-day postoperative and long-term or papilicable applicable				thrombosis, pulmonary embolism etc.), categorised in accordance with the Clavien-
If relevant, was the complication reported to the relevant national agency or pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results the relevant neth				
pharmaceutical company. Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results. Summarise the key results. Summarise the key results. Prevision surgery etc.) If appropriate, whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term State if there were no complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term State if there were no complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term State if there were no complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) Where applicable, specify time 30-day postoperative and long-term or adverse events with relevant raw data or intervention and the properties of the propert				
Specify the duration of time between completion of the intervention and discharge, and whether this was within the expected timeframe (if not, why not). Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Specify the duration and discharge, and whether complications or adverse events were repornational agency or pharmaceutical company Specify time to discharge following completion of intervention and the within the expected timeframe or not (if not, why not) Where applicable, specify the 30-day postoperative and long-term or state if there were no complications or adverse events Key results—comprehensively describe: Rey results—with relevant raw data Include table showing key results				
and whether this was within the expected timeframe (if not, why not). • Where applicable, the 30-day postoperative and long-term morbidity/mortality may need to be specified. • State if there were no complications or adverse outcomes • State if there were no complications or adverse outcomes Discussion 8a Summarise the key results. Summarise the key results. Summarise the key results. morbidity and mortality meetings) • If appropriate, whether complications or adverse events were reporting national agency or pharmaceutical company • Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) • Where applicable, specify the 30-day postoperative and long-term • State if there were no complications or adverse events Key results with relevant raw data • Include table showing key results				 If appropriate, whether complications or adverse events were discussed locally (e.g.
need to be specified. • State if there were no complications or adverse outcomes • State if there were no complications or adverse outcomes • Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) • Where applicable, specify the 30-day postoperative and long-term • State if there were no complications or adverse events Key results—comprehensively describe: • Key results—comprehensively describe: • Key results—twith relevant raw data • Include table showing key results				
• State if there were no complications or adverse outcomes • Specify time to discharge following completion of intervention and within the expected timeframe or not (if not, why not) • Where applicable, specify the 30-day postoperative and long-term • State if there were no complications or adverse events Expected timeframe or not (if not, why not) • Where applicable, specify the 30-day postoperative and long-term • State if there were no complications or adverse events Key results-comprehensively describe: • Key results with relevant raw data • Include table showing key results				If appropriate, whether complications or adverse events were reported to the relevant noticeal example or pharmacountiest company.
within the expected timeframe or not (if not, why not) • Where applicable, specify the 30-day postoperative and long-term • State if there were no complications or adverse events Key results—comprehensively describe: • Key results with relevant raw data • Include table showing key results				
• State if there were no complications or adverse events Discussion 8a Summarise the key results. Key results—comprehensively describe: • Key results with relevant raw data • Include table showing key results				
Discussion 8a Summarise the key results. Key results—comprehensively describe: Key results with relevant raw data Include table showing key results				Where applicable, specify the 30-day postoperative and long-term morbidity/mortality Obta (4 the second long-term morbidity) Obta (5 the second long-term morbidity)
 Key results with relevant raw data Include table showing key results 	Discussion	Q ₂	Summarica the key regulte	
 Include table showing key results 	Diouddiuii	Ja	Commando tito noy roduito.	
8b Relevant Literature and Placing the Results in Context Scientific context and implications—comprehensively describe:				 Include table showing key results
		8b	Relevant Literature and Placing the Results in Context	Scientific context and implications—comprehensively describe:
 Include a discussion of the relevant literature and, if appropriate, similar published Relevant literature and if appropriate, similar published studies Implications for clinical practice and guidelines (e.g. NICE) 				
 Describe the implications for clinical practice guidelines (e.g. NICE) and any relevant Comparison to current gold standard of care 				
hypotheses generated • Relevant hypothesis generation			hypotheses generated	Relevant hypothesis generation

(Continued)

Topic	Item	PROCESS 2020	Proposed PROCESS 2023	
	8c	Strengths Describe the relevant strengths of the study. Detail any multidisciplinary or cross-speciality relevance. Weaknesses and Limitations Describe the relevant weaknesses or limitations of the study. For novel techniques or devices, outline any contraindications and alternatives,	Strengths-comprehensively describe: • Strengths of the study • Any multidisciplinary or cross-speciality relevance	
	8d	potential risks and possible complications if applied to a larger population	Weaknesses and limitations – comprehensively describe: Weaknesses and limitations of the study, with potential impact on results and their interpretation Deviations from protocol, with reasons For novel techniques or devices, outline any contraindications/alternatives and potential	
	8e	Directions for Future Research State how the methodology and findings discussed can impact future research and clinical practice. Describe the questions that have arisen as a result of this study. State the alternative study design(s) best suited to address these questions	risks/complications if applied to a larger population Directions for future research – comprehensively describe: Impact on future research and clinical practice Questions that have arisen as a result of the study Alternative study design(s) best suited to address these questions	
	8f		Cost – comprehensively describe: Cost of intervention Justify cost if intervention more expensive than current gold standard of care Any cheaper alternatives	
Conclusions	9a	Key Conclusions Outline the key conclusions from this study	Key conclusions Outline the key conclusions from this study	
	9b	Rationale • Ensure that any of the conclusions made are supported by a strong rationale	Rationale Explain the rationale behind those conclusions	
	9c	Future Work • Briefly discuss any questions arisen from this study and any differences in approach to patient diagnosis or management which the authors might adopt in future similar studies	Future work – briefly describe: • Any questions arisen from the study • Any differences in approach to patient diagnosis or management which authors might adopt in future similar studies	
Patient and/or Carer Perspective	10	Where appropriate, the patients should be given the opportunity to share their perspective on the intervention(s) they received (e.g. sharing quotes from a consented, anonymised interview, or questionnaire)	Where appropriate, the patients should be given the opportunity to share their perspective on the intervention(s) they received (e.g. sharing quotes from a consented, anonymised interview or questionnaire)	
Informed Consent	11	The authors must provide evidence of consent, where applicable, and if requested by the journal. • State the method of consent at the end of the article (e.g. verbal or written). • If not provided by the patients, explain why (e.g. death of patient and consent provided by next of kin). If the patients or family members were untraceable then document the tracing efforts undertaken	The authors must provide evidence of consent, where applicable, and if requested by the journal • State the method of consent at the end of the article (e.g. verbal or written) • If not provided by the patients, explain why (e.g. death of patient and consent provided by next of kin). If the patients or family members were untraceable then document the tracing efforts undertaken	
Additional Information	12a	State any conflicts of interest	State any conflicts of interest	
	12b	State any sources of funding	State any sources of funding (e.g. grant details) Role of funder	
	12c	Other Relevant Disclosures • Please state any author contributions, acknowledgements, and where required, institutional review board and ethical committee approval. • Disclose whether the case has been presented at a conference or regional meeting	Other relevant disclosures • State any author contributions and acknowledgements • If appropriate, give details of institutional review board and ethical committee approval • Disclose whether the case has been presented at a conference or regional meeting	
Clinical Images and Videos	13	Where relevant and available, include clinical images to help demonstrate the cases pre-, peri-, and postintervention (e.g. radiological, histopathological, patient photographs, intraoperative images), • Where relevant and available, include a link (e.g. Google Drive, YouTube) to the narrated operative video to highlight specific techniques or operative findings. • Ensure all media files are appropriately captioned and indicate points of interest to allow for easy interpretation	Where relevant and available, include clinical images to help demonstrate the cases preperi- and postintervention (e.g. radiological, histopathological, patient photographs, intraoperative images etc.) Where relevant and available, include a link (e.g. Google Drive, YouTube etc.) to the narrated operative video to highlight specific techniques or operative findings Ensure all media files are appropriately captioned and indicate points of interest to allow for easy interpretation	
Referencing the Checklist	14	Include reference to the PROCESS 2020 publication by stating: 'This case series has been reported in line with the PROCESS Guideline' at the end of the methods section (and include citation in the references section)	Include reference to the PROCESS 2023 publication by stating: 'This case series has been reported in line with the PROCESS Guideline' at the end of the methods section and include citation in the references section	

A study published in 2017 evaluated the impact of PROCESS guidelines by comparing the reporting quality of surgical case series that were published in three journals across two time periods: pre-PROCESS period (September 2016 to December 2016) and post-PROCESS period (January 2017 to April 2017); a 5% improvement in the reporting quality of surgical case series was noted following the introduction of PROCESS guidelines^[8]. Since it was designed in 2016, PROCESS guidelines have been cited over 1000 times, further conveying its impact in the field of surgical research^[5–7].

Over 2 years have passed since the previous update to the PROCESS guidelines in 2020^[7]. Our aim is to revise the PROCESS guidelines in accordance with new developments in the field of surgical research and hence maintain the utility of PROCESS guidelines in the surgical research community.

Methods

A PROCESS 2023 steering group was formed; proposals to update PROCESS 2020 guidelines were devised by members of the PROCESS 2023 steering group through collaboration over e-mail and Google Docs.

In a similar fashion to how the initial PROCESS guidelines were created, the Delphi method was used in order to develop PROCESS 2023 guidelines^[5]. Members of the Delphi groups that were involved in the development of previous PROCESS guidelines were emailed invitations to participate in the creation of PROCESS 2023 guidelines. Predominantly, participants who were requested to join the Delphi group, belonged to the editorial board or the pool of reviewers of the International Journal of Surgery Publishing Group (IJSPG), an ardent supporter of the PROCESS guidelines, having employed compliance with the

guidelines as a compulsory requirement for the submission of case series^[7]. Invitees included 53 people, across 21 countries covering 6 continents, in a range of surgical specialities as well as other specialities such as dermatology, gastroenterology, psychiatry, and dental public health.

Those who agreed to participate in the development of PROCESS 2023 guidelines were sent a survey using Google Forms, outlining the proposed changes to the PROCESS 2020 guidelines. Participants were asked to indicate their agreement/ disagreement with the proposed changes to the guidelines, using a nine-point Likert scale, where a score of 1 indicated strong disagreement and a score of 9 indicated strong agreement.

Consensus was deemed as greater than 70% agreement with the proposed changes to an item (i.e. a score between 7 and 9).

Results

A total of 41 out of the 53 invitees expressed an interest in participating in the development of PROCESS 2023 guidelines. Out of those who showed an interest to participate, 38 people completed the Google Forms survey and hence took part in the development of PROCESS 2023 guidelines. Table 1 shows PROCESS 2020 guidelines and the proposed version of PROCESS 2023 guidelines. Table 2 shows a summary of the scores given by the Delphi group members to indicate whether they agree or disagree with the proposed changes made to each item of the PROCESS 2020 guidelines. The majority of the items received a score between 7 and 9 from greater than 70% of the participants, indicating consensus with the proposed changes to those items. However, two items (3c and 6a) received a score between 7 and 9 from less than 70% of the participants, indicating lack of consensus with the proposed changes to those items. Those items will remain unchanged.

Delphi group characteristics

Out of the 38 participants, 16 participants were from Asia, 16 participants were from Europe, 5 participants were from North America, and 1 participant was from Australia. There were no participants from South America or Africa.

Of the 38 participants, eight were from United Kingdom (UK), seven from India, four from United States of America (USA), four from Italy, two from Pakistan, and two from Singapore. There was one participant from each of the following countries: Malaysia, China, Saudi Arabia, Türkiye, Egypt, Australia, Canada, Spain, Portugal, Finland, and Norway.

Contribution from participants across different parts of the world allowed socioeconomic diversity among the Delphi group members; participants belonged to a range of developing and developed countries.

Of the 38 participants, 32 were experts in a range of specialities within the surgical field. Out of the other six participants, two participants were experts in dermatology, one in gastroenterology, one in pulmonary and critical care, one in psychiatry, and one in public health dentistry.

Supplementary Figure 1 (Supplemental Digital Content 1, http://links.lww.com/JS9/B337) shows the characteristics of the Delphi group members.

Table 2

Summary of scores given by Delphi group members to indicate whether they agree or disagree with the proposed changes made to each item of the PROCESS 2020 guidelines.

Item	1–3	4–6	7–9
1	2.6%	10.5%	86.8%
2	5.3%	15.8%	79.0%
3a	2.6%	21.0%	76.4%
3b	7.9%	10.5%	81.6%
3c	2.6%	31.6%	65.8%
3d	2.6%	18.4%	79.0%
3e	2.6%	10.5%	86.8%
4	2.6%	15.8%	81.6%
5	5.2%	15.8%	79.0%
6a	13.1%	21.0%	65.9%
6b	7.9%	18.4%	73.7%
6c	7.8%	5.3%	86.9%
6d	2.6%	5.3%	92.1%
6e	5.3%	15.8%	79.0%
6f	0.0%	10.5%	89.5%
6g	5.3%	13.2%	81.6%
6h	0.0%	15.8%	84.2%
6i	0.0%	5.3%	94.8%
6j	0.0%	10.5%	89.5%
6k	0.0%	21.1%	78.9%
61	2.6%	23.7%	73.7%
6m	0.0%	10.5%	89.5%
6n	0.0%	26.3%	73.7%
7a	0.0%	5.3%	94.7%
7b	0.0%	18.4%	81.6%
7c	0.0%	5.2%	94.7%
7d	0.0%	13.2%	86.8%
7e	0.0%	15.8%	84.2%
8a	5.2%	18.5%	76.4%
8b	2.6%	7.9%	89.5%
8c	5.3%	18.4%	76.3%
8d	0.0%	21.1%	79.0%
8e	0.0%	15.8%	84.3%
8f	2.6%	18.4%	79.0%
9a	5.2%	21.1%	73.7%
9b	7.9%	7.9%	84.3%
9c	0.0%	18.4%	81.7%
10	2.6%	21.0%	76.3%
11	2.6% 5.2%	18.4%	76.3% 76.3%
11 12a	2.6%	13.2%	76.3% 84.3%
12a 12b	2.6% 0.0%	13.2% 5.2%	94.8%
120 12c	0.0%	5.2% 15.7%	94.6% 84.2%
13	0.0%	29.0%	71.0%
14	0.0%	13.2%	86.9%

Discussion

Despite being lower down in the hierarchy of evidence, case series can add to the scientific literature in numerous ways (e.g. describing rare diseases, unusual presentations of a common disease, novel interventions, unexpected results of an intervention etc.)^[2,3]. Given how easy, quick and inexpensive it is to perform case series, they abundantly feature in the surgical literature^[2]. However, the methodological and reporting quality of surgical case series have been shown to be substandard and requiring improvement; this can compromise the utility and trustworthiness of surgical case series^[4]. PROCESS guidelines were introduced to remedy the poor reporting quality among surgical case

PROCESS 2023 guidelines.

PROCESS 2023 Guidelines

Topic	Item	Item description
Title	1	The phrase 'case series' is included
Keywords	2	 The focus of the research study is mentioned (e.g. patient population, setting, diagnosis, intervention, outcome etc.) Include three to six keywords that identify what is covered in the case series (e.g. patient population, setting, diagnosis, intervention, outcome etc.)
		 Include 'case series' as one of the keywords
		 Include the surgical subspeciality the case series pertains to as a keyword
Abstract	3a	Introduction – briefly describe:
		Background Scientific rationals for this study
		 Scientific rationale for this study Overarching theme of the case series
		Aims and objectives
	3b	Methods – briefly describe:
		Sample size
		Timeframe of research
		Characteristics of study design (e.g. prospective/retrospective, single-/multicentre, informal/formal, consecutive/
	20	nonconsecutive, exposure-/outcome-based sampling, clinical/population-based etc.)
	3c	Outcomes • Describe the outcomes of the intervention and management strategy
	3d	Conclusion – briefly describe:
		Key findings and take-home messages
		Impact on future clinical practice
		Direction of future research
	3e	Present a structured abstract
		 Informal case series – introduction, case presentations (brief description of each case) and discussion/conclusion
Highlights	4	 Formal case series – introduction, methods, results and discussion/conclusion Convey the key findings of the research study in 3 to 5 bullet points
Introduction	5	Introduction – comprehensively describe:
	Ü	Relevant background and scientific rationale for case series with reference to key scientific literature
		 Overarching theme (e.g. common patient population, setting, diagnosis, intervention, outcome etc.)
		Aims and objectives
Methods	6a	Registration
		 State the research registry number in accordance with the Declaration of Helsinki - "Every research study involving human subjects must be registered in a publicly accessible database". This can be obtained from, for example, ResearchRegistry. com, ClinicalTrials.gov, or ISRCTN.
		• If a protocol already exists, state the corresponding registration number and access directions (e.g. website or journal, and
	6b	include a hyperlink that is publicly accessible). It must be written in the English language Ethical approval
	Ob	State whether ethical approval was needed or not, with reason(s)
		If appropriate, state name of body giving ethical approval and approval number
	6c	Study design
		•State that the study is a case series
		Describe key characteristics of study design (e.g. prospective/retrospective, single-/multicentre, informal/formal,
	6d	consecutive/nonconsecutive, exposure-/outcome-based sampling, clinical/population-based etc.)
	ou	Setting and timeframe – comprehensively describe: • Geographical location
		 Nature of setting(s) where the patient was managed (e.g. primary/secondary/tertiary care setting, district general hospital/
		teaching hospital, public/private, low-resource setting etc.)
		 Relevant dates (e.g. recruitment, intervention, follow-up, data collection etc.)
	6e	Participants – comprehensively describe:
		•Relevant participant characteristics (e.g. demographics, comorbidities, ASA score, severity of surgery, urgency of surgery,
		smoking status, tumour staging etc.) and if relevant, exposure(s) of the participants (e.g. COVID-19)
		 Subsequent inclusion and exclusion criteria with clear definitions Approach to selecting patients (e.g. consecutive/nonconsecutive, exposure-/outcome-based, formal/informal etc.)
		Methods used to ensure de-identification of patient information
	6f	Recruitment – comprehensively describe:
		Sources of recruitment (e.g. physician referral, electronic health record etc.)
		 Any monetary incentivisation of patients for recruitment and retention should be declared; clarify the nature of any incentives
		provided
	6g	Preintervention patient optimisation:
		 Lifestyle (e.g. weight loss, nutritional support, exercise, smoking cessation etc.)

(Continued)

PROCESS 2023 Guidelines

Topic	Item	Item description
		 Medication review (e.g. anticoagulation, oral hypoglycemics, insulin, oral contraceptive pill etc.) Presurgical stabilisation/preparation (e.g. treating hypothermia/-volemia/-tension, ICU care, nil by mouth, bowel
		preparation etc.)
		Other (e.g. psychological support, preoperative education/counselling etc.)
	6h	Interventions — comprehensively describe:
		 Type of intervention (e.g. pharmacological, surgical, physiotherapy, psychological etc.)
		 Aim of intervention (preventative/therapeutic)
		Concurrent treatments (e.g. antibiotics, analgesia, antiemetics, venous thromboembolism prophylaxis etc.)
	6i	Intervention specifics – comprehensively describe:
		Rationale for the treatment offered Table in the internal in the administration of the internal income.
		Techniques involved in the administration of the intervention Time to intervention
		 Time to intervention For pharmacological therapies, include details such as formulation, dosage, strength, route and duration
		• For surgical intervention, include details on anaesthesia, patient positioning, preparation used, equipment needed,
		devices, sutures, surgical stage etc.Degree of novelty of surgical technique/device (e.g. 'first in human' or 'first in this context')
		Manufacturer and model of any medical devices used
	6j	Operator details — comprehensively describe:
	oj	 Relevant training, specialisation and operator's experience (e.g. average number of the relevant procedures performed annually, independent, needs direct/indirect supervision etc.)
		Learning curve for technique
		Requirement for additional training
	6k	Quality control – comprehensively describe:
		• Measures taken to reduce inter- or intra-operator/operation variation, ensure quality and maintain consistency between
		cases (e.g. independent observers, lymph node counts, standard surgical technique etc.)
	OI.	Any specific disparities between cases Parker with a constant of the case of the cas
	61	Postoperative care and follow-up – comprehensively describe:
		 Postoperative care (e.g. patient education, postoperative medications, early mobilisation, targeted physiotherapy, early enteral nutrition, early removal of catheters/drains, psychological therapy etc.)
		 Follow-up time-frames (e.g. first follow-up post-discharge, follow-up duration at the time of submission etc.) and frequency
		 Follow-up setting (e.g. home via phone/video consultation, primary care, secondary care etc.)
		Follow-up method (e.g. history, clinical examination, blood tests, imaging etc.)
		Follow-up personnel (e.g. operating surgeon) Any propries long term granufflance requirements (e.g. imaging surgeillance of endourseuler engine repair aligned).
		 Any specific long-term surveillance requirements (e.g. imaging surveillance of endovascular aneurysm repair, clinical/ ultrasound examination of regional lymph nodes for skin cancer etc.)
		State if any participants were lost to follow-up and why
Results	7a	Participants – comprehensively describe:
riodato	7 4	Number of patients involved
		 Patient characteristics (e.g. demographics, comorbidities, ASA score, severity of surgery, urgency of surgery, smoking status, tumour staging etc.) and if relevant, exposure(s) of the participants
		 Include table showing baseline patient characteristics
	7b	Deviation from the initial management plan – comprehensively describe:
		 Any changes to the planned intervention with rationale
		If appropriate, include a suitable schematic diagram
	7c	Outcomes and follow-up — comprehensively describe:
		 Expected versus attained clinician assessed outcome, providing reference to scientific literature used to inform expected outcomes (e.g. core outcome set) ◆ If appropriate, include patient-reported outcomes (e.g. quality-of-life) ◆ Percentage of
		patients lost to follow-up with rationale
	7d	Intervention adherence and compliance — comprehensively describe:
	7 u	 Assessment of patient's adherence and tolerability of intervention and postoperative instructions (e.g. avoiding heavy
		lifting/strenuous activity, tolerance of chemotherapy/pharmacological agents etc.) • Impact on long-term applicability of
		intervention in clinical practice
	7e	Complications and adverse events – comprehensively describe:
		 Precautionary measures taken to prevent complications (e.g. antibiotic/venous thromboembolism prophylaxis)
		 Complications and adverse events (e.g. blood loss, wound infection, deep vein thrombosis, pulmonary embolism etc.), categorised in accordance with the Clavien-Dindo classification
		Timing of adverse events
		Mitigation for adverse events (e.g. blood transfusion, wound care, re-exploration/revision surgery etc.)
		 If appropriate, whether complications or adverse events were discussed locally (e.g. morbidity and mortality meetings) If appropriate, whether complications or adverse events were reported to the relevant national agency or pharmaceutical

(Continued)

PROCESS 2023 Guidelines

Topic	Item	Item description
		company
		• Specify time to discharge following completion of intervention and whether this was within the expected timeframe or not (if
		not, why not)
		 Where applicable, specify the 30-day postoperative and long-term morbidity/mortality
	_	State if there were no complications or adverse events
Discussion	8a	Key results – comprehensively describe:
		Key results with relevant raw data
	Oh	Include table showing key results Calcuttific and the distributions approach and itself and the distributions are stable and t
	8b	Scientific context and implications – comprehensively describe:
		 Relevant literature and if appropriate, similar published studies Implications for clinical practice and guidelines (e.g. NICE)
		Comparison to current gold standard of care
		Relevant hypothesis generation
	8c	Strengths – comprehensively describe:
	00	Strengths of the study
		Any multidisciplinary or cross-speciality relevance
	8d	Weaknesses and limitations – comprehensively describe:
		 Weaknesses and limitations of the study, with potential impact on results and their interpretation
		Deviations from protocol, with reasons
		• For novel techniques or devices, outline any contraindications/alternatives and potential risks/complications if applied to a
		larger population
	8e	Directions for future research – comprehensively describe:
		Impact on future research and clinical practice
		 Questions that have arisen as a result of the study
		 Alternative study design(s) best suited to address these questions
	8f	Cost – comprehensively describe:
		• Cost of intervention
		Justify cost if intervention more expensive than current gold standard of care
Canalysiana	0.0	Any cheaper alternatives Any cheaper alternatives
Conclusions	9a	Key conclusions
	9b	Outline the key conclusions from this study Rationale
	90	Explain the rationale behind those conclusions
	9c	Future work — briefly describe:
	30	Any questions arisen from the study
		 Any differences in approach to patient diagnosis or management which authors might adopt in future similar studies
Patient and/or Carer	10	Where appropriate, the patients should be given the opportunity to share their perspective on the intervention(s) they received
Perspective		(e.g. sharing quotes from a consented, anonymised interview or questionnaire)
Informed Consent	11	The authors must provide evidence of consent, where applicable, and if requested by the journal
		• State the method of consent at the end of the article (e.g. verbal or written)
		• If not provided by the patients, explain why (e.g. death of patient and consent provided by next of kin). If the patients or
		family members were untraceable then document the tracing efforts undertaken
Additional Information	12a	State any conflicts of interest
	12b	State any sources of funding (e.g. grant details)
		• Role of funder
	12c	Other relevant disclosures
		State any author contributions and acknowledgements
		If appropriate, give details of institutional review board and ethical committee approval
Olivia al Ivano a a a d	10	Disclose whether the case has been presented at a conference or regional meeting
Clinical Images and	13	Where relevant and available, include clinical images to help demonstrate the cases pre-, peri- and postintervention (e.g.
Videos		radiological, histopathological, patient photographs, intraoperative images etc.)
		Where relevant and available, include a link (e.g. Google Drive, YouTube etc.) to the narrated operative video to highlight specific techniques or operative findings.
		specific techniques or operative findings
Referencing the	14	 Ensure all media files are appropriately captioned and indicate points of interest to allow for easy interpretation Include reference to the PROCESS 2023 publication by stating: 'This case series has been reported in line with the PROCESS
Checklist	14	Guideline' at the end of the methods section and include citation in the references section
OHOGNIOU		duration at the one of the interiors seemen and monde change in the references seemen

series and a study conducted shortly after the introduction of PROCESS guidelines showed a 5% improvement in the reporting quality of surgical case series^[5,8].

A study in 2017 showed that out of 193 surgical journals that were analysed, the majority (62%) did not require their authors to conform to any reporting guidelines, which in turn are integral to making research trustworthy and useful^[9].

PROCESS guidelines have already made a substantial impact in the field of surgical research, having been cited over 1000 times since its inception^[5–7]. In order to maintain its value and applicability in the surgical research field, PROCESS guidelines were updated; some of the key updates are discussed below.

Item 3b in the abstract section and 6d in the methods section have been amended to encourage authors to specify characteristics of the study design (e.g. prospective/retrospective, single-/multicentre, informal/formal, consecutive/nonconsecutive, exposure-/outcome-based sampling, clinical/population-based etc.). Substandard reporting of study designs makes it difficult for readers to effectively scrutinise and/or compare research studies and hence diminishes their usefulness. Revisions have been made to items 3b and 6d with a view to improving the reporting of study designs among surgical case series^[10].

Item 3e has been added to the abstract section, encouraging authors to present their abstract in a structured fashion. This will allow the readers to gain a quick overview of the research study, its salient findings and how the author(s) arrived at those findings^[11]. Structured abstracts have been noted to convey information with a higher quality in comparison to unstructured abstracts^[12].

Items 6h and 6m in the methods section have been amended, in order to prompt authors to report any strategies that were adopted in line with the Enhanced Recovery After Surgery (ERAS) protocol (e.g. preoperative counselling, early mobilisation, early enteral nutrition, early removal of catheters/drains etc.)^[13]. ERAS is a relatively new concept within the surgical field and aims to improve the postoperative recovery and outcomes in patients^[14]. Positive outcomes such as reduction in length of hospital stay, hospital costs, and rates of postoperative complications have been noted with the implementation of ERAS protocol^[13]. Hence, authors are urged to report any measures that were undertaken as per the ERAS protocol so that readers can judge whether patients received care as per the current evidence-based surgical practice whilst scrutinising patient outcomes.

Item 8f in the discussion section reminds authors to report their analysis of cost-effectiveness. Researchers, policy makers, and clinicians evaluate the cost-effectiveness of an intervention in comparison to the gold standard of care when determining research priorities and making decisions regarding funding health services^[15].

Table 3 presents the updated PROCESS 2023 guidelines; we urge journals, editors, reviewers and authors to adopt these guidelines and hence contribute to the improvement of the reporting quality of surgical case series.

Authors should cite PROCESS 2023 guidelines in their methods section and provide a completed PROCESS 2023 checklist along with their manuscript for scrutiny by the reviewers and editors in order to ensure optimal research reporting. To guarantee accessibility, we will update the PROCESS website (https://www.processguideline.com/) with the PROCESS 2023 guidelines checklist, providing it in a variety of formats.

Conclusion

We have presented the updated version of PROCESS guidelines. In order to improve the reporting quality of surgical case series, we encourage journals, editors, reviewers, and authors to utilise these guidelines.

PROCESS Group

Burcin Ekser¹, James McCaul², Zubing Mei³, Duilio Pagano⁴, Shahzad Raja⁵, Veeru Kasivisvanathan⁶, Todd Manning⁷, Salim Surani⁸, Salvatore Giordano⁹, Diana Miguel¹⁰, Iain Nixon¹¹, Patrick Bradley¹², Nicholas Raison¹³, Mangesh Thorat¹⁴, Achilleas Thoma¹⁵, James Chi-Yong Ngu¹⁶, Joerg Albrecht¹⁷, Prabudh Goel¹⁸, Nan Zun Teo¹⁹, Syed Ather Enam²⁰, Huseyin Kadioglu²¹, C S Pramesh²², M Hammad Ather²³, Juan Gómez Rivas²⁴, Samuele Massarut²⁵, Mushtaq Chalkoo²⁶, Prathamesh Pai²⁷, Rolf Wynn²⁸, Somprakas Basu²⁹, Ashwini Rao³⁰, Ashraf Noureldin³¹, Roberto Coppola³², Mohammad Bashashati³³, Baskaran Vasudevan³⁴, Raafat Afifi³⁵, Andrew Beamish³⁶, Kandiah Raveendran³⁷, Alessandro Coppola³⁸

¹Department of Surgery, Indiana University School of Medicine, USA. ²Queen Elizabeth University Hospital, Glasgow, UK; Institute of Cancer Therapeutics, University of Bradford, UK. ³Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, China. ⁴IRCCS-ISMETT University of Pittsburgh Medical Centre, Italy. ⁵Harefield Hospital, UK. ⁶University College London, UK. ⁷Bendigo Health, Australia. ⁸Texas A&M University, USA. ⁹Turku University Hospital, Finland; The University of Turku, Finland. 10 Champalimaud Clinical Centre, Portugal. 11NHS Lothian, UK; University of Edinburgh, UK. 12 Nottingham University Hospitals, Queens Medical Centre, UK. ¹³Kings College London, UK. ¹⁴Breast Services, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust, UK; Centre for Cancer Prevention, Wolfson Institute of Population Health, Queen Mary University of London, UK; School of Cancer & Pharmaceutical Sciences, Faculty of Life Sciences & Medicine, King's College London, UK. 15 McMaster University, Canada. ^{16,19}Changi General Hospital, Singapore. ¹⁷Cook County Health and Hospital System, USA. ¹⁸All India Institute of Medical Sciences, New Delhi, India. 20, 23 Aga Khan University, Pakistan. ²¹Yeni Yüzyıl University, Turkiye. ²², ²⁷Tata Memorial Centre, Homi Bhabha National Institute, India. ²⁴Hospital Clínico San Carlos, Spain. ²⁵Centro di Riferimento Oncologico Aviano IRCCS, Italy. ²⁶Government Medical College, Srinagar, Kashmir, India. ²⁸UiT The Arctic University of Norway, Norway. ²⁹All India Institute of Medical Sciences, Rishikesh, India. ³⁰Manipal Academy of Higher Education, Manipal, India. ³¹Almana Hospital, Khobar, Saudi Arabia. ³²Campus Bio Medico University - Fondazione Campus Bio Medico, Italy. ³³Dell Medical School, The University of Texas at Austin, USA. 34MIOT Hospital, Chennai, India. 35Faculty of Medicine, Cairo University, Egypt. 36Swansea University Medical School, UK. ³⁷Fatimah Hospital, Malaysia. ³⁸Department of Surgery, Sapienza University of Rome, Italy.

Ethical approval

Not applicable.

Consent

Not applicable.

Sources of funding

Not applicable.

Author contribution

R.A.: concept and design, data interpretation and analysis, draughting, revision, and approval of final manuscript; G.M.: design, data collection, data interpretation and analysis, draughting, revision, and approval of final manuscript; C.S., T.F., M.N., and A.K.: design, data interpretation and analysis, draughting, revision, and approval of final manuscript. Delphi group members: design of PROCESS 2023 guidelines.

Conflicts of interest disclosure

The authors have no financial, consultative, institutional, or other relationships that might lead to bias or conflict of interest.

Research registration unique identifying number (UIN)

Not applicable.

Guarantor

Riaz Agha.

Data availability statement

The data in this guideline is derived from individual responses to the DELPHI survey and so is confidential and not in the public domain.

Provenance and peer review

Not applicable.

References

- Torres-Duque CA, Patino CM, Ferreira JC. Case series: an essential study design to build knowledge and pose hypotheses for rare and new diseases.
 J Bras Pneumol 2020;46:e20200389.
- [2] Coroneos CJ, Chin BH. Evaluating case series in surgeryThoma A, Sprague S, Voineskos S, Goldsmith C. Evidence-based surgery. Springer; 2019:183–191.
- [3] Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med 2001;134:330–4.
- [4] Agha RA, Fowler AJ, Lee SY, et al. Systematic review of the methodological and reporting quality of case series in surgery. Br J Surg 2016;103:1253–8.
- [5] Agha RA, Fowler AJ, Rajmohan S, et al. PROCESS Group. Preferred reporting of case series in surgery; the PROCESS guidelines. Int J Surg 2016;36(Pt A):319–23.
- [6] Agha RA, Borrelli MR, Farwana R, et al. PROCESS Group. The PROCESS 2018 statement: updating consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. Int J Surg 2018;60:279–82.
- [7] Agha RA, Sohrabi C, Mathew G, et al. PROCESS Group. The PROCESS 2020 guideline: updating consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. Int J Surg 2020;84:231–5.
- [8] Agha RA, Borrelli MR, Farwana R, et al. Impact of the PROCESS guideline on the reporting of surgical case series: a before and after study. Int J Surg 2017;45:92–7.
- [9] Agha RA, Barai I, Rajmohan S, et al. Support for reporting guidelines in surgical journals needs improvement: a systematic review. Int J Surg 2017:45:14-7.
- [10] Liberati A, Altman DG, Tetzlaff J, et al. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Int Med 2009;151:W65–94.
- [11] PLOS. How to write an abstract. PLOS. 2022. Accessed 09 November 2023. https://plos.org/resource/how-to-write-a-great-abstract/
- [12] Sharma S, Harrison JE. Structured abstracts: do they improve the quality of information in abstracts? Am J Orthod Dentofacial Orthop 2006;130: 523–30.
- [13] Altman AD, Helpman L, McGee J, et al. Enhanced recovery after surgery: implementing a new standard of surgical care. CMAJ 2019;191:E469–75.
- [14] Yingchun S, Lu X, Jinhui H, et al. Meta-analysis of enhanced recovery after surgery protocols for the perioperative management of paediatric colorectal surgery. J Pediatr Surg 2023;58:1686–93.
- [15] Catalá-López F, Ridao M, Alonso-Arroyo A, et al. The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review. Syst Rev 2016;5:6.